Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Fiorelli

Urology Plains, PA Doctor of Osteopathy

NPI 1568463784 CMS profile 25901

670 S River St Ste 301, Plains, PA 18705

Open in the dashboard

General payments

$7,089

355 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Fiorelli of Plains, PA is reported in the CMS Open Payments database as having received $7,089 across 355 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,724 61
2024 General $1,281 51
2023 General $1,192 65
2022 General $664 34
2021 General $771 44
2020 General $805 53
2019 General $652 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Fiorelli
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Robert Fiorelli were reported at $1,724. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Robert Fiorelli Urology median Middle half National median
2019 $652 $480 $147–$1,201 $163
2020 $805 $246 $87–$645 $114
2021 $771 $358 $111–$1,000 $132
2022 $664 $476 $143–$1,263 $149
2023 $1,192 $560 $168–$1,461 $160
2024 $1,281 $563 $170–$1,464 $164
2025 $1,724 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $997 63 payments
  2. Axonics Modulation Technologies, Inc. $855 55 payments
  3. Sumitomo Pharma America, Inc. $808 40 payments
  4. Janssen Biotech, Inc. $798 30 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $750 27 payments
  6. AbbVie, Inc. $746 40 payments
  7. Pfizer Inc. $511 34 payments
  8. Medtronic, Inc. $264 5 payments
  9. Urogen Pharma, Inc. $160 10 payments
  10. Actelion Pharmaceuticals US, Inc. $122 1 payment
  11. Other $1,078 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,654 350 payments
  2. Education $435 5 payments
Products named General payments · program years 2019–2025
  1. XTANDI $899 61 payments
  2. GEMTESA $812 40 payments
  3. ERLEADA $735 26 payments
  4. Nubeqa $694 24 payments
  5. Xofigo $464 15 payments
  6. Axonics r-SNM System $374 25 payments
  7. MYRBETRIQ $343 33 payments
  8. BOTOX $308 15 payments
  9. LUPRON DEPOT $268 15 payments
  10. Axonics $256 12 payments
  11. Other $2,809 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

5,943

Median for Urology: 1,053

Drug cost

$992,275

Median for Urology: $101,464

Branded share of claims

33.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 46 $650,859
Myrbetriq Mirabegron Brand 201 $110,260
Tamsulosin Hcl Generic 981 $24,594
Trospium Chloride Er Trospium Chloride Brand 137 $23,964
Dutasteride Generic 496 $19,678
Elmiron Pentosan Polysulfate Sodium Brand 21 $18,617
Gemtesa Vibegron Brand 24 $18,042
Alfuzosin Hcl Er Alfuzosin Hcl Brand 891 $17,754
Bethanechol Chloride Generic 187 $13,388
Tolterodine Tartrate Er Tolterodine Tartrate Brand 188 $13,108

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$197,071

Of which drugs: $25,412

Medicare patients

1,148

Average age 76

Services billed

5,440

218 women, 930 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 40%
Diabetes 36%
Chronic kidney disease 29%
Cancer 28%
Atrial fibrillation 23%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 22 172 $24,026

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $187
$187 24 —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $131
$131 — —
BOTOX
  • AbbVie, Inc. $126
$126 — —
XTANDI
  • Astellas Pharma US Inc $100
  • PFIZER INC. $15
$115 46 —
ERLEADA
  • Janssen Biotech, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

355 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record